MedTrace Logo

Caffeine Consumption in Glaucoma Patients and Healthy Subjects

NCT03675412 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-11-14

No results posted yet for this study

Summary

Caffeine is the most widely consumed drinking nutrient in the world. Caffeine effects various organs and the vascular system. It decreases ocular blood flow due to vasoconstriction.

Conditions

  • Glaucoma, Primary Open Angle

Interventions

DIETARY_SUPPLEMENT

Caffeine tablet

Each eligible participant will receive one 200 mg caffeine tablet to ingest after completing all baseline study tasks.

Sponsors & Collaborators

  • Wills Eye

    lead OTHER

Principal Investigators

  • M. Reza Razeghinejad, MD · Wills Eye Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-12-30
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03675412 on ClinicalTrials.gov